Effects of green tea extract on oxidative stress and renal function in diabetic individuals: A randomized, double-blinded, controlled trial

2018 ◽  
Vol 46 ◽  
pp. 195-201 ◽  
Author(s):  
Sáskia Ribeiro Vaz ◽  
Luiza Moreira Nogueira de Amorim ◽  
Pamella Vanessa Freitas de Nascimento ◽  
Valéria Soares Pigozzi Veloso ◽  
Marina Sayuri Nogueira ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Renal Function ◽  
Green Tea ◽  
Controlled Trial ◽  
Green Tea Extract ◽  
Tea Extract ◽  
Double Blinded

scholarly journals Green Tea Extract Ameliorates Learning and Memory Deficits in Ischemic Rats via Its Active Component Polyphenol Epigallocatechin-3-gallate by Modulation of Oxidative Stress and Neuroinflammation

2012 ◽  
Vol 2012 ◽  
pp. 1-11 ◽  
Author(s):  
Kuo-Jen Wu ◽  
Ming-Tsuen Hsieh ◽  
Chi-Rei Wu ◽  
W. Gibson Wood ◽  
Yuh-Fung Chen
Keyword(s):  
Oxidative Stress ◽  
Nitric Oxide ◽  
Learning And Memory ◽  
Green Tea ◽  
Memory Impairment ◽  
Memory Deficits ◽  
Green Tea Extract ◽  
Morris Water Maze Test ◽  
Learning And Memory Deficits ◽  
Tea Extract

Ischemic stroke results in brain damage and behavioral deficits including memory impairment. Protective effects of green tea extract (GTex) and its major functional polyphenol (−)-epigallocatechin gallate (EGCG) on memory were examined in cerebral ischemic rats. GTex and EGCG were administered 1 hr before middle cerebral artery ligation in rats. GTex, EGCG, and pentoxifylline (PTX) significantly improved ishemic-induced memory impairment in a Morris water maze test. Malondialdehyde (MDA) levels, glutathione (GSH), and superoxide dismutase (SOD) activity in the cerebral cortex and hippocampus were increased by long-term treatment with GTex and EGCG. Both compounds were also associated with reduced cerebral infraction breakdown of MDA and GSH in the hippocampus. Inin vitroexperiments, EGCG had anti-inflammatory effects in BV-2 microglia cells. EGCG inhibited lipopolysaccharide- (LPS-) induced nitric oxide production and reduced cyclooxygenase-2 and inducible nitric oxide synthase expression in BV-2 cells. GTex and its active polyphenol EGCG improved learning and memory deficits in a cerebral ischemia animal model and such protection may be due to the reduction of oxidative stress and neuroinflammation.

scholarly journals Green Tea Potentially Ameliorates Bisphenol A-Induced Oxidative Stress: AnIn VitroandIn SilicoStudy

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Hiral Suthar ◽  
R. J. Verma ◽  
Saumya Patel ◽  
Y. T. Jasrai
Keyword(s):  
Oxidative Stress ◽  
Bisphenol A ◽  
Green Tea ◽  
Binding Capacity ◽  
Venous Blood ◽  
Green Tea Extract ◽  
High Dose ◽  
Healthy Human ◽  
Tea Extract ◽  
Dose Dependent

The present investigation was an attempt to elucidate oxidative stress induced by bisphenol A on erythrocytes and its amelioration by green tea extract. For this, venous blood samples from healthy human adults were collected in EDTA vials and used for preparation of erythrocytes suspension. When erythrocyte suspensions were treated with different concentrations of BPA/H2O2, a dose-dependent increase in hemolysis occurred. Similarly, when erythrocytes suspensions were treated with either different concentrations ofH2O2(0.05–0.25 mM) along with BPA (50 μg/mL) or 0.05 mMH2O2along with different concentrations of BPA (50–250 μg/mL), dose-dependent significant increase in hemolysis occurred. The effect of BPA andH2O2was found to be additive. For the confirmation, binding capacity of bisphenol A with erythrocyte proteins (hemoglobin, catalase, and glutathione peroxidase) was inspected using molecular docking tool, which showed presence of various hydrogen bonds of BPA with the proteins. The present data clearly indicates that BPA causes oxidative stress in a similar way asH2O2. Concurrent addition of different concentrations (10–50 μg/mL) of green tea extract to reaction mixture containing high dose of bisphenol A (250 μg/mL) caused concentration-dependent amelioration in bisphenol A-induced hemolysis. The effect was significant (P<0.05). It is concluded that BPA-induced oxidative stress could be significantly mitigated by green tea extract.

The MIRACLE trial: A randomized, controlled trial comparing green tea extract versus placebo for the prevention of metachronous colon adenomas in a screening population.

2015 ◽  
Vol 33 (3_suppl) ◽  
pp. TPS786-TPS786 ◽  
Author(s):  
Thomas Jens Ettrich ◽  
Julia Stingl ◽  
Rainer Muche ◽  
Katrin Claus ◽  
Baerbel Reiser ◽  
...  
Keyword(s):  
Green Tea ◽  
Controlled Trial ◽  
Epigallocatechin Gallate ◽  
Genetic Alterations ◽  
Colorectal Polyps ◽  
Green Tea Extract ◽  
Colorectal Adenomas ◽  
Tissue Samples ◽  
Increased Risk ◽  
Tea Extract

TPS786 Background: Prevention of colorectal cancer is a major health care issue. After polypectomy there is an increased risk of polyp recurrence and various means of chemoprevention have been tried to prevent this. NSAIDs have been shown to be effective but confer side effects such as gastrointestinal bleeding. Nutraceuticals such as polyphenols from tea plants have demonstrated remarkable therapeutic and preventive effects in molecular, epidemiological and some clinical trials. However, their value in preventing colorectal polyps has not been demonstrated in a large, randomized trial. The beneficial safety profile of decaffeinated green tea extract and accumulating evidence of its cancer preventive potential justify and require, in our view, a validation of this compound for the nutriprevention of colorectal adenoma. Good accessibility and low costs might render this neutraceutical a top candidate for wider use as nutritional supplement in colon cancer prevention. Methods: Randomized, double blinded, placebo-controlled, multicenter trial. After a one month run-in period with verum, 918 patients (age: 50-80 years) who have undergone polypectomy within the last 6 months will be randomized to receive either decaffeinated green tea extract (containing 150 mg epigallocatechin gallate (EGCG) two times daily) or placebo over a period of three years. Primary outcome: Incidence of metachronous colorectal adenomas (tubulovillous, tubular, villous, serrated lesions) at the 3 year follow-up colonoscopy. Secondary outcomes: Occurrences, number, localization, size and histological subtypes of adenomas, frequency of colorectal carcinoma. In addition, genetic and biochemical biomarkers in blood samples and genetic alterations (Ras, B-raf, microRNAs) in tissue samples of adenomas will be analyzed (biobanking subprojects). Additionally, nutrikinetics and nutrigenetics of EGCG and other catechins will be assessed in healthy volunteers. Patient recruitment has started in November 2011. At September 2014, 785 patients were recruited and 651 patients were randomized. We expect the last patient out in Spring 2018. (Trial identifier NCT01360320) Clinical trial information: NCT01360320.

Sign in / Sign up

Export Citation Format

Share Document